DCIS Team Project

Abbreviated Name
DCIS Team Project
Lead Investigator
Li, ChristopherFred Hutchinson Cancer Center
Coordinating Investigator
No coordinating investigator
Involved Investigators

Abstract

Both overtreatment and undertreatment of DCIS are pervasive problems given that no useful approaches for identifying which DCIS patients are likely or highly unlikely to go on to develop invasive breast cancer are currently available. The identification of useful markers could have considerable clinical impact in guiding both treatment and follow-up decision making.

Aims

Diagnosis of IBC in either breast at least 6 months after the diagnosis of DCIS.

Analytic Method

A.   Preliminary Phase             Candidate markers will be selected in the preliminary phase if they have good performance on their own (defined as TPR>0.3, corresponding to FPR= 0.2) or if they contribute substantially to a combination score (defined as increasing the TPR corresponding to FPR=0.2 by 0.05). TPR corresponding to FPR= 0.2 will be derived from time dependent ROC curves that will be calculated using event rates and minimal clinical data for subjects in the underlying cohort and biomarker data for subjects in the nested case-control subset. Time dependent ROC curves compare marker distributions in biomarker controls (defined as those alive and without IBC 7 years after diagnosis with DCIS) with marker distributions in cases (subjects who develop IBC within 5 years of DCIS diagnosis). Markers will be combined into a score using relative risk regression with cross validation to correct for over fitting. Time dependent ROC curves will then be calculated for the combination score. We will proceed with the evaluation phase only if data from the preliminary phase are sufficiently promising, i.e. a marker or marker combination is found that appears to have the target performance specified in the sample size calculations.        Although the preliminary phase concerns primarily selection of markers for evaluation, we will also use the preliminary phase data to test some hypotheses concerning markers recently reported by Kerlikowske, et al. for women treated with lumpectomy alone, namely p16, COX-2, and Ki-67,24 as well as any other promising candidates reported in the literature. Using the marker cut-offs defined by Kerlikowske and colleagues, we will compare sensitivities and specificities in our study with theirs. They also defined risk categories based on markers and mode of detection. We will test if rates of IBC in those categories are comparable estimated rates observed in our study for women treated with lumpectomy alone. Regardless of these results we will also perform analyses more extensive than those reported by Kerlikowske, including time dependent ROC analyses for individual markers and for marker combinations. B.   Evaluation Phase       In the evaluation phase more extensive analyses will be conducted for the preliminary phase marker combination and for individual markers selected in the preliminary phase.       Relative risks beyond those conferred by other predictors will be examined using relative risk regression models. Other predictors will include demographic factors (age, race/ethnicity, etc.), established breast cancer risk factors (e.g., first degree family history of breast cancer, use of menopausal hormone therapy, body mass index, etc.), DCIS tumor characteristics (e.g., size, histology, grade, etc.), DCIS treatments, and mode of DCIS detection.       To evaluate discrimination ROC curves will be calculated. ROC curves will be compared for different biomarkers. We will especially focus on the marker co

Outcome

Both overtreatment and undertreatment of DCIS are pervasive problems given that no useful approaches for identifying which DCIS patients are likely or highly unlikely to go on to develop invasive breast cancer are currently available. The identification of useful markers could have considerable clinical impact in guiding both treatment and follow-up decision making.

Publications

  • No publications available at this time for this protocol.

Biomarkers

Data Collections

There is one collection of data that has not yet been made public. Logging in may you give you access to the names of the non-public data collections.

 Team Project
Start Date
Aug 13 2010
Estimated Finish Date
Jun 13 2013
Finish Date
Mar 31 2016
Protocol ID
351
Protocol Type
Reference Set
Fields of Research
  • Proteomics
Collaborative Group
Breast and Gynecologic Cancers Research Group
Cancer Types
  • Malignant neoplasm of breast
Phased Status
2

Associated Forms